Targeting gonadal androgen synthesis (often in conjunction with blockade of androgen receptor) is the cornerstone of treatment of hormone-sensitive metastatic prostate cancer (HSPC).
Despite the failure of androgen deprivation therapy, most tumors maintain some dependence on androgen or androgen receptor signaling for proliferation. This article reviews the current standard of care for metastatic HSPC, mechanisms of treatment resistance, novel drugs targeting the androgen signaling pathway, biomarkers predicting response to treatment and survival, future directions, and ongoing clinical trials in HSPC.
Written by:
Agarwal N, Hussain M. Are you the author?
Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Suite 2123, Salt Lake City, UT 84112, USA.
Reference: Hematol Oncol Clin North Am. 2013 Dec;27(6):1221-41.
doi: 10.1016/j.hoc.2013.08.007
PubMed Abstract
PMID: 24188260
UroToday.com Prostate Cancer Section
